Literature DB >> 21537353

Peripheral neuropathies: Establishing common clinical research standards for CIDP.

Hans-Peter Hartung, Helmar C Lehmann, Hugh J Willison.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21537353     DOI： 10.1038/nrneurol.2011.46

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R A C Hughes; K C Gorson; D Cros; J Griffin; J Pollard; J-M Vallat; S L Maurer; K Riester; G Davar; K Dawson; A Sandrock
Journal:  Neurology       Date:  2010-02-23       Impact factor: 9.910

Review 2.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Hubertus Köller; Bernd C Kieseier; Sebastian Jander; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  Composite versus individual measures of disease activity in rheumatoid arthritis.

Authors:  Tuhina Neogi; David T Felson
Journal:  J Rheumatol       Date:  2008-02       Impact factor: 4.666

Review 4.  Diagnosis and treatment in inflammatory neuropathies.

Authors:  M P T Lunn; H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-03       Impact factor: 10.154

5.  Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial.

Authors:  Ivo N van Schaik; Filip Eftimov; Pieter A van Doorn; Esther Brusse; Leonard H van den Berg; W Ludo van der Pol; Catharina G Faber; Joost C H van Oostrom; Oscar J M Vogels; Rob D M Hadden; Bert U Kleine; Anouk G W van Norden; Jan J G M Verschuuren; Marcel G W Dijkgraaf; Marinus Vermeulen
Journal:  Lancet Neurol       Date:  2010-02-02       Impact factor: 44.182

6.  Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice.

Authors:  Kenneth C Gorson; Ivo N van Schaik; Ingemar S J Merkies; Richard A Lewis; Richard J Barohn; Carol L Koski; David R Cornblath; Richard A C Hughes; Angelika F Hahn; Mona Baumgarten; Jonathan Goldstein; Jonathan Katz; Michael Graves; Gareth Parry; Pieter A van Doorn
Journal:  J Peripher Nerv Syst       Date:  2010-12       Impact factor: 3.494

7.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors:  Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

8.  Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.

Authors: 
Journal:  Lancet Neurol       Date:  2009-01-10       Impact factor: 44.182

Review 9.  Treating nerves: a call to arms.

Authors:  Richard A C Hughes
Journal:  J Peripher Nerv Syst       Date:  2008-06       Impact factor: 3.494

Review 10.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217
  10 in total
  2 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

2.  Progress in Recognizing and Treating Polyneuropathy.

Authors:  Bernd C Kieseier; Hans-Peter Hartung
Journal:  Dtsch Arztebl Int       Date:  2018-02-09       Impact factor: 5.594
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.